Recent

% | $
Quotes you view appear here for quick access.

Merck & Co. Inc. Message Board

  • jc_magical_mystery_tour jc_magical_mystery_tour Feb 4, 2013 12:31 PM Flag

    S&P Reiterates Buy Opinion on MRK

    February 1, 2013
    11:52 am ET ... S&P REITERATES BUY OPINION ON SHARES OF MERCK (MRK
    42.00****):We lower our 2013 EPS estimate $0.05 to $3.70, which at the upper end
    of MRK's $3.60-$3.70 guidance range. However, we maintain our 12-month target
    price of $51, applying a modest premium to peers P/E of 12.7X to our $4.00 EPS
    estimate for 2014. Impacted by generic erosion in Singulair, Q4 2012 EPS fell 14%
    to $0.83, in line with our estimate. Despite recent setbacks, we still see promise in
    the R&D pipeline, with four major filings completed last year. Other positives
    include strength in the diabetes franchise, vaccines and emerging markets. The
    dividend yields 4.1%. /H. Saftlas

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MRK
57.610.00(0.00%)Apr 20 4:03 PMEDT